In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Shire, Barr settle Adderall XR litigation; sign three deals

Executive Summary

In a litigation settlement with Shire, Barr Pharmaceuticals' Barr Laboratories division cannot market generic versions of Adderall XR (mixed amphetamine) for attention deficit hyperactivity disorder in the US until April 1, 2009, unless another company launches a generic formulation of the drug.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies